Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Page 1 of 1212345...10...Last »

Promius Pharma Launches New Corporate Brand Identity

Promius Pharma LLC, a subsidiary of Dr. Reddy’s Laboratories, unveiled its new visual identity and corporate brand: The Power of Humans Being.

Read More »

Omnicom Health Group launches DDB Health

Omnicom Health Group announced that it is creating DDB Health, a dedicated, integrated healthcare network combining several U.S. and European professional healthcare agencies.

Read More »

Tesaro’s ovarian cancer drug study succeeds

Tesaro Inc.’s experimental ovarian cancer drug niraparib met the main goal of prolonging survival in patients – without the disease worsening – in a late-stage trial.

Read More »

FDA asks for more data on over-the-counter hand sanitizers

The U.S. FDA is requesting additional data to support the safety and effectiveness of certain active ingredients used in topical consumer antiseptic rubs, including hand sanitizers, that are sold over-the-counter.

Read More »

Shire says ADHD drug meets main goal of study

Irish drugmaker Shire Plc said a study testing an experimental drug to treat attention-deficit disorder met the main goal, bringing the drug one step closer to approval in the United States.

Read More »

FDA does not approve Lipocine’s testosterone drug

Lipocine Inc. said its oral testosterone replacement product did not get the approval in the United States, sending the drugmaker’s shares down 52 percent in premarket trading.

Read More »

Esperion Falls on Lack of FDA Clarity for Cholesterol Drug

Esperion Therapeutics is on track to initiate global pivotal Phase 3 studies and global cardiovascular outcomes trial in fourth-quarter 2016 for Bempedoic Acid.

Aligned with global regulatory authorities on a consistent definition of statin intolerance

Read More »

FDA names Pazdur head of new Oncology Center of Excellence

The U.S. Food and Drug Administration’s high-profile cancer drug director, Dr. Richard Pazdur, has been named head of a newly created Oncology Center of Excellence that will coordinate the review of all the agency’s cancer therapeutics.

Read More »

FDA Advisory Committee recommends approval of Jardiance for cardiovascular indication in 12-11 vote

A U.S. Food and Drug Administration Advisory Committee voted 12-11 that substantial evidence exists to establish that Jardiance (empagliflozin) reduces cardiovascular (CV) death in adults with type 2 diabetes and established CV disease. Jardiance, which is marketed by Boehringer Ingelheim and Eli Lilly, is the only oral T2D medicine shown in a clinical trial to reduce the risk of CV death.

Read More »

White House chides Congress for failing to fund Zika

White House spokesman Josh Earnest chided Republicans for failing to push forward with the president’s request for funding to combat the Zika virus and address an urgent public health crisis.

Read More »

FDA approves Gilead’s hep C drug Epclusa

The U.S. Food and Drug Administration approved Gilead Sciences Inc.’s drug for treating chronic hepatitis C virus infection.

Read More »

Senate Democrats seek new deal on Zika funding fight

U.S. Senate Democrats called for bipartisan talks in the funding fight over Zika, saying a Republican proposal was “extreme and insufficient” to combat the virus and was full of “ideological poison pill riders.”

Read More »

Can smartphones help improve heart attack treatment?

Smartphones, social media and crowdsourcing all have the potential to help people get faster, better treatment for heart attacks and strokes, according to the American Heart Association (AHA).

Read More »

In Light of Two Major Failed Trials, FORUM Pharma Closes Its Doors This Week

It’s official – Waltham, Massachusetts-based FORUM Pharmaceuticals will be shuttering its doors before the Fourth of July holiday.

Read More »

Infinity Pharma Cuts Jobs by 58% as AbbVie Terminates Duvelisib Collaboration Deal

Infinity Pharmaceuticals announced that North Chicago-based AbbVie chose to terminate its collaboration deal to develop and commercialize duvelisib, a dual inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma, which are associated with malignant B-cells.

Read More »

Mayne Pharma Acquiring 42 Generic Drugs

Australian company Mayne Pharma is acquiring 37 approved drugs and five products that have been filed with the U.S. FDA from Teva Pharmaceutical Industries and Allergan.

Read More »

Pfizer invests in its first biotech hub in Asia

Pfizer Inc. will invest $350 million to build a biotech center in China, the latest in a series of moves by pharma industry giants to set up shop in the world’s no. 2 drugs market.

Read More »

Supreme Court refuses to review prenatal test patent dispute

The U.S. Supreme Court rejected a bid to review a legal fight over the cancellation of a patent on a less-risky form of prenatal testing, in a case that has left many companies and trade groups worried that important discoveries may no longer qualify for patents.

Read More »

NewLink Genetics Stock Slides, Company Lays Off 87 After Failed Trial

After announcing that its Phase III clinical trial for algenpantucel-KL for resected pancreatic cancer failed in May, Ames, Iowa-based NewLink Genetics confirmed that it has laid off 87 employees.

Read More »

AnGes Terminates Phase III HGF Plasmid, Starts New Plan

AnGes MG Inc. announced its decision to amend the global development strategy of HGF Plasmid (AMG0001, Beperminogene Perplasmid) for the treatment of critical limb ischemia.

Read More »

Page 1 of 1212345...10...Last »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

August 2018 Focus: Top 200 Meds, Year After Launch, VR/AR and more!


Ad Right Bottom